Oncotelic Therapeutics, Inc. (OTLC)
Oxford Ledge is still expanding full research coverage of OTLC. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Oncotelic develops cancer and disease treatments through subsidiaries and a joint venture, focusing on FDA-designated rare pediatric indications.
Source: 10-K (2025-12-31) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- 8-K Entry into material agreement; Creation of direct financial obligation; 3.02; Financial statements and exhibits 2026-06-29
- 10-Q Quarterly financial report (unaudited) 2026-05-14
- 8-K Entry into material agreement; Completion of acquisition or disposition; 3.02; Financial statements and exhibits 2026-05-05
- 8-K Other material event; Financial statements and exhibits 2026-04-16
- 10-K Annual financial report with audited statements 2026-04-15
Source: SEC EDGAR.
Annual results
5 years of annual figures for OTLC, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | — | $249.3M | $0.59 |
| 2024 | — | -$4.5M | -$0.01 |
| 2023 | $70,000 | -$7.9M | -$0.02 |
| 2022 | — | $5.1M | $0.01 |
| 2021 | — | -$9.4M | -$0.03 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for OTLC. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open OTLC in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.